

RealRate Inc., 2040 Martin Ave., Santa Clara, CA 95050



RealRate

July 10, 2026


To the CEO
Vertex Pharmaceuticals
INC MA
50 NORTHERN AVENUE
BOSTON, MA 02210
USA

Vertex Pharmaceuticals INC MA TOP Rated in the US Pharmaceutical Ranking

Dear Sir or Madam,

at RealRate we have just published the 2026 US Pharmaceutical ranking. I am happy to inform you that Vertex Pharmaceuticals INC MA has been TOP Rated at rank 25 out of 178.

Overall, 178 US companies were analyzed with respect to their financial strength. The complete rating is published at <https://www.realrate.ai/rankings>. Your individual rating report, showing your strengths compared to your competitors is attached.



RealRate is an international rating agency based in Santa Clara and Berlin. We use artificial intelligence to create fair and explainable company ratings. Customers highly appreciate the RealRate rating seal: only the strongest companies are able to offer highly attractive and innovative products with top customer services. Billion dollar companies rely on our rating and build trust with their customers.

You too can acquire the RealRate seal and advertise with it. We only reach out to the top-rated companies, like yours and only those may subscribe for our seal. Save a lot of money and effort compared to traditional rating agencies: get a RealRate seal for just \$9,900. Simply sign the attached order form and send it back via email.

Please feel free to book a short video call with me: <https://calendly.com/holger-bartel>


Sincerely,

Dr. Holger Bartel, CEO

RealRate Seal Subscription

RealRate Inc.
2040 Martin Ave., Santa Clara, California 95050, USA
Via email to: holger.bartel@realrate.ai

We subscribe to the Pharmaceutical RealRate rating for Vertex Pharmaceuticals INC MA. The subscription comprises the annual rating update. The invoice will be sent annually, provided that a TOP rating is achieved again. The subscription can be cancelled by written letter, effective for the following year.



RealRate provides the rating seal as a scalable vector graphic. It can be used without any restrictions by Vertex Pharmaceuticals INC MA (Customer) for all promotional purposes, i.e. in product brochures, presentations, websites and broadcasting.

Item	2026 US Pharmaceutical RealRate rating seal for Vertex Pharmaceuticals INC MA
Amount	USD 9,900
Order no.	2026-0000875320

Amounts payable by Customer are exclusive of taxes. Customer is responsible for all his taxes and will pay such amounts invoiced by RealRate.

Billing address


Company name	Full name
Street address	Department
City	Phone number
State / province	Email address
ZIP code	
Country	

Shipping address

The electronic RealRate rating seal and the invoice will be sent to
Delivery email

Vertex Pharmaceuticals INC MA

Date, location, name



The relative strengths and weaknesses of Vertex Pharmaceuticals INC MA are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vertex Pharmaceuticals INC MA compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 69% points. The greatest weakness of Vertex Pharmaceuticals INC MA is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 351%, being 122% points above the market average of 229%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	11,201,000	Assets	25,643,000
Cost of Goods Sold	1,651,300	Liabilities	6,977,200
Intangible Assets	1,512,200	Expenses	8,531,300
Liabilities, Current	3,861,200	Revenues	12,001,300
Liabilities, Non-Current	3,116,000	Stockholders Equity	18,665,800
Other Assets	12,929,800	Net Income	3,953,200
Other Compr. Net Income	-143,700	Comprehensive Net Income	3,881,350
Other Expenses	1,084,400	BaseVar	26,889,850
Other Liabilities	0	ECR before LimitedLiability	273%
Other Net Income	483,200	Economic Capital Ratio	351%
Other Revenues	12,001,300		
Property and Equipment	0		
Research and Development	4,042,500		
Selling, General and Administrative Expense	1,753,100		